Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and perceptions of e-cigarette use in orthodontic patients: A cross-sectional survey.

Journal of orthodontics·2026
Same author

Early-Stage Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same author

Gender- and age-specific patterns of tennis-related injuries in pediatric populations: Insights from emergency room data (2014-2023).

Injury·2026
Same author

Early-Stage Hodgkin Lymphoma: Time for Novel Agents?

Hematology/oncology clinics of North America·2026
Same author

Fast-acting antidepressants trigger presynaptic BDNF release and structural plasticity at mouse mossy fiber-CA3 synapses.

bioRxiv : the preprint server for biology·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.

Varun Iyengar1, Kishan Patel1, Alison Moskowitz1

  • 1Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cancers
|June 26, 2026
PubMed
Summary
This summary is machine-generated.

Frontline therapy for advanced classic Hodgkin lymphoma (cHL) has evolved from chemotherapy to targeted treatments, improving survival rates. Current strategies balance efficacy and toxicity reduction for better patient outcomes.

Keywords:
ABVDBEACOPPPD-1 blockadePET-adapted therapyadvanced-stage Hodgkin lymphomabrentuximab vedotincirculating tumor DNAclassic Hodgkin lymphoma

Related Experiment Videos

Last Updated: Jun 27, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Area of Science:

  • Oncology
  • Hematology
  • Clinical Therapeutics

Background:

  • Advanced-stage classic Hodgkin lymphoma (cHL) survival has significantly improved, exceeding 80% long-term survival.
  • Treatment has evolved from early chemotherapy regimens to modern, biologically informed strategies.

Purpose of the Study:

  • To review the evolution of frontline therapy for advanced-stage cHL.
  • To examine the transition from empiric chemotherapy to contemporary, biologically informed treatment strategies.
  • To discuss the integration of novel agents and future directions.

Main Methods:

  • Review of historical and contemporary treatment approaches for advanced-stage cHL.
  • Analysis of chemotherapy regimens (MOPP, ABVD, BEACOPP).
  • Evaluation of PET-adapted therapy and novel agents (brentuximab vedotin, PD-1 blockade).

Main Results:

  • Early chemotherapy regimens (MOPP, ABVD) established curability of advanced lymphoma.
  • Treatment intensification (BEACOPP) improved disease control but increased toxicity.
  • PET-adapted therapy and novel agents enhance outcomes and reduce toxicity.

Conclusions:

  • Frontline therapy for advanced cHL has shifted from maximizing cytotoxic intensity to personalized strategies.
  • Novel agents and biomarker-driven approaches are refining treatment to optimize cure and minimize harm.
  • Future research focuses on risk stratification and circulating tumor DNA for further treatment refinement.